Ads For New Drugs Would Require FDA Preclearance Under Rx Safety Bill
Executive Summary
Promotional materials for recently-approved drugs would receive special scrutiny by the Center for Postmarket Drug Evaluation & Research proposed in Senate legislation
You may also be interested in...
Senior FDA Staff Has Final Say Over Disputes In Enzi/Kennedy Drug Safety Bill
Senior FDA officials will have final say over drug safety disputes under proposed legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.)
Senior FDA Staff Has Final Say Over Disputes In Enzi/Kennedy Drug Safety Bill
Senior FDA officials will have final say over drug safety disputes under proposed legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.)
Enzi/Kennedy Drug Safety Bill Will Expand FDA’s Oversight Armamentarium
Drug safety legislation from Senate Health Committee Chairman Michael Enzi (R-Wyo.) will make FDA's enforcement authority more subtle than merely having the ability to pull drugs from the market